ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

ANZMTG 02.14 CombiRT Trial - An open-label, single-arm, phase I/II, multicenter study to evaluate safety and efficacy of combination of dabrafenib, trametinib and palliative radiotherapy in metastatic BRAF mutation positive cutaneous melanoma

An open-label, single-arm, phase I/II, multicenter study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy in patients with unresetable (stage IIIc) and metastatic (stage IV) BRAF V600E/K mutation-positive cutaneous melanoma


Study Status:
Proposed
ANZ Clinical Trials Registry # - ACTRN12615000292572 
ClinicalTrials.gov identifier - NCT02392871

Principal Investigator's details:
Dr Tim Wang
Crown Princess Mary Cancer Centre
tim.wang1@health.nsw.gov.au

ANZMTG coordinator details:
The Poche Centre, 40 Rocklands Road, North Sydney NSW 2060
Email:anzmtg0214@melanoma.org.au
Phone: +61 2 9911 7352


Documents (PDF downloads):

 


Return to Previous Page